Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX:ACB) (OTCQB:ACBFF) (Frankfurt: 21P; WKN:A1C4WM) and CanniMed Therapeutics Inc. (TSX:CMED) ("CanniMed") today announced that Aurora has completed the acquisition of all issued and outstanding shares of CanniMed Therapeutics Inc. ("CanniMed") that it did not already own.

"We have now fully completed the largest acquisition in the history of the cannabis sector and continue to progress well with our integration activities to accelerate growth of both Aurora and CanniMed," said Terry Booth. "CanniMed, which will operate as a wholly-owned subsidiary of Aurora, will be spearheading a number of initiatives such as scientific research, education and product development. The capabilities and reputation of the CanniMed team in the medical market are very strong, which we will leverage to further grow our penetration of this rapidly growing segment of the international cannabis market."

The shares were acquired pursuant to the compulsory acquisition procedures of the Canada Business Corporations Act (the "Compulsory Acquisition"), and relates to those CanniMed shares that were not tendered to Aurora's offer to acquire all of the CanniMed Shares dated November 24, 2017, as amended by the notice of change dated January 12, 2018, the notice of variation dated February 5, 2018 (the "Notice of Variation") and the notice of variation and extension dated March 9, 2018 (the "Offer"). The Offer expired at 11:59 p.m. (Pacific Time) on March 24, 2018.

The approximately 1.2 million CanniMed Shares were acquired for a consideration of approximately 3.4 million Aurora shares and $1.7 million in cash. The CanniMed Shares were de-listed from the Toronto Stock Exchange ("TSX") as at the close of business on May 1, 2018.

CanniMed intends to make an application to the applicable Canadian securities regulatory authorities as soon as practicable to cease to be a reporting issuer in each province in which it is currently a reporting issuer.